No single medication or therapy universally outperforms Adderall for ADHD. But if Adderall isn’t working well for you, whether because of side effects, inconsistent results, or supply problems, several alternatives have strong clinical evidence behind them. The best option depends on why Adderall isn’t cutting it.
What “better” means varies from person to person. For some, it’s fewer side effects. For others, it’s longer-lasting focus, less anxiety, or a treatment that doesn’t involve stimulants at all. Here’s what the evidence actually supports.
Other Stimulants: The Most Common Switch
Adderall is a blend of amphetamine salts. If it’s not working, the most straightforward move is trying a different stimulant, because the two main stimulant families (amphetamine-based and methylphenidate-based) affect the brain differently enough that many people respond well to one but not the other. Roughly 30% of people who don’t respond to one stimulant class do respond to the other.
Methylphenidate-based options include brand names like Ritalin, Concerta, and Focalin. These work on the same neurotransmitters as Adderall but through a slightly different mechanism. Current treatment guidelines from the American Academy of Pediatrics recommend FDA-approved medications alongside behavioral strategies for anyone six and older, without singling out one stimulant over another. The choice between amphetamine and methylphenidate is largely about individual response.
Extended-release formulations can also make a meaningful difference. If you’re on immediate-release Adderall and struggling with crashes or inconsistent coverage throughout the day, switching to a long-acting version (Adderall XR, Vyvanse, or extended-release methylphenidate) may solve the problem without changing drug classes entirely. Vyvanse, a prodrug that your body converts into its active form gradually, tends to produce smoother effects with less of a peak-and-crash pattern.
Non-Stimulant Medications
If stimulants as a category aren’t right for you, perhaps because of anxiety, cardiovascular concerns, tics, or substance use history, several non-stimulant medications are FDA-approved for ADHD. They’re generally considered second-line treatments because their effect sizes are smaller than stimulants, but for the right person, they can work well.
Atomoxetine (Strattera) was the first non-stimulant approved for ADHD. It works by increasing norepinephrine availability in the brain. It takes several weeks to reach full effect, unlike stimulants that work within an hour. The tradeoff is 24-hour coverage without the peaks and valleys of stimulant dosing, and no abuse potential.
Viloxazine (Qelbree) is a newer option approved in 2021. In clinical trials involving 774 patients, 44% were classified as responders, meaning they experienced at least a 50% reduction in symptom scores after six weeks. Among those rated “much improved” by clinicians, symptom scores dropped by roughly 80%. It’s particularly worth discussing with your provider if atomoxetine didn’t work, since viloxazine has a distinct mechanism despite both being non-stimulants.
Alpha-2 agonists like guanfacine (Intuniv) and clonidine (Kapvay) are another category. These are especially useful when hyperactivity, impulsivity, or emotional reactivity are the dominant symptoms, and they’re sometimes added alongside a stimulant rather than replacing it entirely.
Cognitive Behavioral Therapy
Therapy doesn’t replace medication for most people with moderate to severe ADHD, but the evidence for cognitive behavioral therapy (CBT) as a standalone treatment is stronger than many expect. A study of 124 adults with ADHD compared 12 weeks of structured CBT alone against CBT combined with medication. Both groups showed significant improvements in core ADHD symptoms, including inattention and impulsivity-hyperactivity scores. The combination wasn’t statistically superior for core symptoms or emotional well-being. The CBT-only group actually showed greater improvement in physical quality of life.
This doesn’t mean therapy is “as good as” Adderall across the board. What it does suggest is that structured CBT, the kind focused on building organizational systems, managing time, and addressing the thought patterns that come with ADHD, can meaningfully reduce symptoms. For people who can’t tolerate medication or prefer not to use it, CBT is a legitimate path rather than a consolation prize. It also tends to produce benefits that persist after treatment ends, something medication alone doesn’t do.
Dietary Changes
Diet modifications are sometimes dismissed as fringe, but the clinical evidence for one specific approach is surprisingly strong. Elimination diets, sometimes called “few-foods diets,” involve stripping your diet down to a handful of low-reactivity foods for several weeks, then systematically reintroducing items to identify triggers. In two controlled trials involving 120 children, 68% were classified as responders, showing at least a 40% reduction in ADHD symptom scores. One of those trials saw a 78% response rate.
The catch is that these diets are extremely restrictive and difficult to maintain, especially for children. They require close supervision and aren’t practical as a permanent solution. But they can reveal food sensitivities (artificial colors, preservatives, dairy, wheat) that worsen symptoms in a specific individual. If you identify and remove those triggers, the long-term dietary adjustment is much more manageable than the elimination phase.
Omega-3 fatty acid supplements have more modest effects. A meta-analysis of 16 trials covering over 1,400 participants found that omega-3 supplementation produced a small but reliable improvement in ADHD symptoms, with an effect size of 0.26. That’s roughly one-third the effect of stimulant medication. Omega-3s showed consistent benefits for hyperactivity across both parent and teacher reports, though effects on inattention were less consistent. They’re not a replacement for medication, but they may provide a helpful boost, particularly for people already on a treatment plan.
Trigeminal Nerve Stimulation
The Monarch eTNS system is an FDA-cleared device worn on the forehead during sleep. It delivers low-level electrical stimulation to a branch of the trigeminal nerve, which connects to brain regions involved in attention and arousal. It’s currently approved for children ages 7 to 12 who aren’t on ADHD medication.
In a controlled trial, 52% of children using the active device improved by at least one level on a clinical severity scale after four weeks, compared to just 14% using a sham device. Average symptom scores dropped from 34 to 23 in the active group. The effect size was classified as medium. Side effects were minimal, mostly mild skin irritation or drowsiness. It’s a genuinely non-pharmacological option, though the evidence base is still smaller than what exists for medication or therapy, and it hasn’t been widely studied in adults.
Combining Treatments
The most effective approach for many people isn’t finding one thing that beats Adderall. It’s building a treatment stack. CDC guidelines emphasize that treatments “often work best when used together,” and this matches the clinical reality: a lower dose of medication combined with CBT, exercise, sleep optimization, and dietary awareness often outperforms a higher dose of any single medication.
If Adderall is partially working but not enough, adding structured therapy or addressing sleep and nutrition may close the gap more effectively than increasing your dose or switching medications. If Adderall’s side effects are the problem, a non-stimulant at a lower intensity combined with behavioral strategies can sometimes match the symptom control you were getting, without the downsides.
What Genetic Testing Can and Can’t Tell You
Pharmacogenomic testing, which analyzes how your genes affect drug metabolism, is increasingly marketed for ADHD medication selection. The reality is less exciting than the marketing. For stimulants specifically, the Canadian Paediatric Society’s review of the evidence found that the gene-drug interactions for methylphenidate and common genetic variants are too weak to guide clinical decisions. No treatment adjustments based on genetic testing are currently recommended for ADHD stimulants.
Genetic testing can be more useful for certain non-stimulant medications or co-prescribed drugs like antidepressants, where metabolism differences between individuals are more clinically meaningful. But if a company is promising to find your “perfect ADHD medication” through a cheek swab, that’s ahead of where the science actually is. Trial and careful observation remain the most reliable way to find what works for you.